|
|
|
| Research progress on polymorphism of drug-related genes in essential hypertension |
| REN Guoqing1 YI Tianjiao2 ZHAO Youyun3 LIU Junshan4 WU Yuanfa5▲ |
1.The First Affiliated Hospital of Yangtze University, Hubei Province, Jingzhou 434000, China;
2.School of Laboratory Medicine, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430000, China;
3.Department of Laboratory Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
4.Department of Laboratory Medicine, Chuzhou Maternal and Child Health Care and Family Plainning Service Center, Anhui Province, Chuzhou 239000, China;
5.Department of Laboratory Medicine, Jingzhou Center for Disease Control and Prevention, Hubei Province, Jingzhou 434000, China |
|
|
|
Abstract Essential hypertension is the most common chronic cardiovascular disease, controlling blood pressure through drugs is the main means to treat hypertension and reduce its complications. However, individual differences of antihypertensive drugs are very common in clinical practice, which is mainly related to the variation of metabolic enzymes, receptors, and other drug targets of antihypertensive drugs. The purpose of this article is to review the relationship and mechanism between gene polymorphisms associated with seven antihypertensive drugs and individual differences in hypertension drugs, and formulat different treatment regimens according to individual genetic variation of metabolic enzymes, receptors and other drug targets associated with antihypertensive drugs, so as to implement individualized and precise treatment.
|
|
|
|
|
|
[1] Mills KT，Stefanescu A，He J. The global epidemiology of hypertension [J]. Nat Rev Nephrol，2020，16（4）：223-237.
[2] 中国高血压防治指南修订委员会，高血压联盟（中国，中华医学会心血管病学分会中国医师协会高血压专业委员会），中国医疗保健国际交流促进会高血压分会，等.中国高血压防治指南（2018年修订版）[J].中国心血管杂志，2019，24（1）：24-56.
[3] Chen K，Xiao P，Li G，et al. Distributive characteristics of the CYP2C9 and AGTR1 genetic polymorphisms in Han Chinese hypertensive patients：a retrospective study [J].BMC Cardiovasc Disord，2021，21（1）：73.
[4] 王申，张舜华，薛薇.沙坦类药物代谢酶CYP2C9的基因遗传多态性在高血压患者中的分布特征[J].中国循证心血管医学杂志，2021，13（6）：712-715.
[5] Pedreros-Rosales C，Jalil-Milad R，Lagos-Lucero M，et al. Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients [J]. Rev Med Chil，2019，147（12）：1527-1534.
[6] Dong H，Wang FZ，Shi K，et al. Association of Cytochrome P450 2C9*3 and Angiotens in Ⅱ Receptor 1 （1166A>C） Gene Polymorphisms With the Antihypertensive Effect of Irbesartan [J]. Am J Hypertens，2021，34（1）：121.
[7] Zhou Y，Ingelman-Sundberg M，Lauschke VM. Worldwide Distribution of Cytochrome P450 Alleles： A Meta-analysis of Population-scale Sequencing Projects [J]. Clin Pharmacol Ther，2017，102（4）：688-700.
[8] 任凌雁，靳倩，廖喆.贵州原发性高血压人群相关药物基因多态性研究[J].重庆医学，2019，48（23）：4017-4019， 4023.
[9] Byeon JY，Kim YH，Lee CM，et al. CYP2D6 allele frequencies in Korean population，comparison with East Asian，Caucasian and African populations，and the comparison of metabolic activity of CYP2D6 genotypes [J]. Arch Pharm Res，2018，41（9）：921-930.
[10] 李艳翠，方芳，方舟.CYP2D6*10/ADRB1基因导向治疗对美托洛尔药动学药效学的影响[J].黑龙江医药科学，2019，42（5）：5-8.
[11] 王玉红，胡晓芳，刘静.沈阳地区高血压患者CYP3A5基因多态性与钙离子通道阻滞剂氨氯地平的相关性研究[J].国际检验医学杂志，2019，40（19）：2420-2422.
[12] Li Z，Chen P，Zhou T，et al. Association between CYP3A5 genotypes with hypertension in Chinese Han population：A case-control study [J]. Clin Exp Hypertens，2017，39（3）：235-240.
[13] Liang H，Zhang X，Ma Z，et al. Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential Hypertension [J]. Pharmgenomics Pers Med，2021，14：189-197.
[14] Galaviz-Hernandez C，Lazalde-Ramos BP，Lares-Assef I，et al. Influence of Genetic Admixture Components on CYP3A5*3 Allele-Associated Hypertension in Amerindian Populations From Northwest Mexico [J]. Front Pharmacol，2020，11：638.
[15] 喻晶，杨璐，张舒琼.7个高血压药物相关基因的多态性在582例汉族高血压患者中的分布[J].国际检验医学杂志，2021，42（3）：325-328，333.
[16] 温改艳，陆瑶，邢晓为.β1肾上腺素受体基因多态性与高血压易感性及治疗的研究进展[J].中国临床药理学与治疗学，2016，21（2）：225-230.
[17] Kitsios GD，Zintzaras E. Synopsis and data synthesis of genetic association studies in hypertension for the adrenergic receptor family genes： the CUMAGAS-HYPERT database [J]. Am J Hypertens，2010，23（3）：305-313.
[18] 王晶，董天崴，王爽.β1-肾上腺素受体、血管紧张素Ⅱ-1型受体基因多态性与高寒地区高血压的关系研究[J].中国全科医学，2020，23（30）：3823-3828.
[19] Wu D，Li G，Deng M，et al. Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to beta-blocker therapy in hypertension [J]. J Int Med Res，2015，43（3）：424-434.
[20] Chen L，Xiao T，Chen L，et al. The Association of ADRB1 and CYP2D6 Polymorphisms With Antihypertensive Effects and Analysis of Their Contribution to Hypertension Risk [J]. Am J Med Sci，2018，355（3）：235-239.
[21] Liu DX，Zhang YQ，Hu B，et al. Association of AT1R polymorphism with hypertension risk： An update meta-analysis based on 28，952 subjects [J]. J Renin Angiotensin Aldosterone Syst，2015，16（4）：898-909.
[22] 董辉，王凤珍，拾坤.细胞色素P450酶2C9*3和血管紧张素Ⅱ1型受体（1166A＞C）基因多态性与原发性高血压的发生及厄贝沙坦降压疗效的关系[J].中华高血压杂志，2020，28（6）：532-538.
[23] Sun Y，Liao Y，Yuan Y，et al. Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen： results from the study of optimal treatment in hypertensive patients with anti-AT1-receptor autoantibodies trial [J]. J Am Soc Hypertens，2014，8（1）：21-27.
[24] 刘龙梅，周双艳，杨泽华.ACE基因多态性人群分布及其在原发性高血压中的高表达研究[J].实用检验医师杂志，2018，10（3）：132-134.
[25] Abouelfath R，Habbal R，Laaraj A，et al. ACE insertion/deletion polymorphism is positively associated with resistant hypertension in Morocco [J]. Gene，2018，658：178-183.
[26] Sun F，He N，Zhang K，et al. Association of ACE gene A2350G and I/D polymorphisms with essential hypertension in the northernmost province of China [J]. Clin Exp Hypertens，2018，40（1）：32-38.
[27] 李露，李铭扬，王祥宇.ACE基因插入/缺失多态性与中国原发性高血压患者ACEI降压效果及咳嗽风险关联性的Meta分析[J].临床心血管病杂志，2017，33（3）：251-257.
[28] 黄红，李燕，全胜麟.原发性高血压血管紧张素转化酶基因I/D多态性与厄贝沙坦降压疗效及血浆肾素血管紧张素-醛固酮系统水平的相关性[J].中国老年学杂志，2017，37（24）：6057-6059.
[29] 杨梅，肖智林，陈晓彬.抗高血压药物相关基因多态性在长沙县区高血压病人群中的分布[J].临床心血管病杂志，2019，35（6）：559-563.
[30] Lynch AI，Boerwinkle E，Davis BR，et al. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension [J]. JAMA，2008，299（3）：296-307. |
|
|
|
